KYTX · XBRL financial data
Kyverna Therapeutics financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (KYTX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Research and development | 112,473 | 133,720 |
| General and administrative | 30,131 | 36,107 |
| Total operating expenses | 142,604 | 169,827 |
| Operating income (loss) | (142,604) | (169,827) |
| Interest income | 15,359 | 9,094 |
| Interest expense | 142 | 489 |
| Other income (expense) | (90) | (85) |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (127,477) | (161,307) |
| Earnings per share, basic USD per share | (3.33) | (3.64) |
| Earnings per share, diluted USD per share | (3.33) | (3.64) |
| Weighted average shares, basic thousands of shares | 38,335 | 44,260 |
| Weighted average shares, diluted thousands of shares | 38,335 | 44,260 |
Balance sheet
CSVFiscal years (KYTX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 96,621 | 124,093 |
| Marketable securities | 189,358 | 155,160 |
| Prepaid and other current assets | 4,622 | 3,700 |
| Total current assets | 290,601 | 282,953 |
| Property and equipment, net | 3,347 | 1,546 |
| Right-of-use asset | 6,468 | 3,568 |
| Total assets | 304,645 | 293,826 |
| Accounts payable | 4,624 | 5,306 |
| Total current liabilities | 33,756 | 36,487 |
| Long-term debt | — | 24,743 |
| Lease liability, non-current | 4,160 | 320 |
| Total liabilities | 38,058 | 61,550 |
| Accumulated deficit | (263,520) | (424,827) |
| Total stockholders' equity | 266,587 | 232,276 |
| Total liabilities and equity | 304,645 | 293,826 |
| Common shares outstanding (cover page) thousands of shares | 43,215 | 60,440 |
Cash flows
CSVFiscal years (KYTX's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (127,477) | (161,307) |
| Stock-based compensation | 8,357 | 10,080 |
| Depreciation and amortization | 2,133 | 1,799 |
| Net cash from operating activities | (114,250) | (153,712) |
| Purchases of property and equipment | 2,205 | 5 |
| Net cash from investing activities | (160,902) | 40,015 |
| Proceeds from issuing common stock | 0 | 16,940 |
| Net cash from financing activities | 337,113 | 141,168 |
| Net change in cash | 61,961 | 27,471 |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Kyverna Therapeutics | 31,806 | not reported | (40,306)* | 61.8M | 4.9 quarters | 10-QJun 30, 2026 |
| Whitehawk Therapeutics | 85,234 | 0 | (14,529)* | 57.0M | 13.1 quarters | 10-QJun 30, 2026 |
| Veru | 23,880 | not reported | (5,467)* | 17.1M | 4.4 quarters | 10-QJun 30, 2026 |
| Lifevantage | 14,920 | 42,377* | 4,767* | 12.5M | — | 10-KJun 30, 2026 |
| Medicinova | 25,416 | 458 | (1,920)* | 49.2M | 13.2 quarters | 10-QJun 30, 2026 |
| Corbus Pharmaceuticals Holdings | 23,370 | not reported | (29,626)* | 19.3M | 4.0 quarters | 10-QJun 30, 2026 |
| PDS Biotechnology | 5,596 | not reported | (2,793)* | 56.0M | 2.0 quarters | 10-QJun 30, 2026 |
| Sutro Biopharma | 54,335 | 9,839 | (38,290)* | 16.6M | 4.3 quarters | 10-QJun 30, 2026 |
| Seres Therapeutics | 17,528 | 593 | (10,477)* | 10.2M | 1.1 quarters | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.